# Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

> **NCT04582669** · PHASE4 · TERMINATED · sponsor: **Montefiore Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Intralesional Triamcinolone 10 mg/mL
- **DRUG:** Intralesional Triamcinolone 20 mg/mL
- **DRUG:** Intralesional Triamcinolone 40 mg/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04582669
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-24
- **Primary completion:** 2022-10-12
- **Final completion:** 2022-10-12
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** This study was administratively closed.
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582669, "Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04582669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*